Novartis’ US generics business Sandoz was won European approval for the biosimilar Ziextenzo (pegfilgrastim), in the same indications as its reference product, Neulasta.
The therapy is approved as a treatment to reduce neutropenia and incidence of febrile neutropenia in adult patients treated with chemotherapy for certain cancers.
Global biopharma head Stefan Hendriks said: "With the approval of Ziextenzo, a long-acting version of oncology supportive medicine filgrastim, we look forward to providing a treatment option that delivers the possibility of further reducing both the personal and financial burden of cancer."
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze